PlainRecordsImipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection
Also listed by FDA as RECARBRIO
On FDA's list as to be discontinued: 1 package from 1 company. Last updated by FDA Sept. 9, 2026. Data from openFDA as of Nov. 12, 2026; FDA's own database can be newer. Not medical advice: ask your pharmacist or doctor before changing or stopping a medicine.
Packages of this drug on FDA's current shortage list, as of openFDA's export of Nov. 12, 2026: none listed.
FDA lists it as to be discontinued.To be discontinued (1)
- Discontinued Sept. 9, 2026RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)Merck Sharp & Dohme LLC
Every entry as FDA lists it (1)
To be discontinued (1)
Merck Sharp & Dohme LLC
Contact: 800-672-6372
- Discontinued Sept. 9, 2026RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)Related information: To be discontinued on or near late September 2026.
First posted Sept. 9, 2026 · updated Sept. 9, 2026
Data provided by the U.S. Food and Drug Administration through openFDA, as of Nov. 12, 2026; FDA's drug shortage database can be newer. openFDA's own note on this data: "Do not rely on openFDA to make decisions regarding medical care." This is not medical advice: ask your pharmacist or doctor before changing or stopping a medicine.